The Science of the Art of Palliative Care

Sponsor
Dartmouth-Hitchcock Medical Center (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05137782
Collaborator
Dartmouth College (Other)
20
1
1
9.9
2

Study Details

Study Description

Brief Summary

This feasibility pilot study is designed to learn whether patients and their care partners (e.g., family members) are willing and able to complete two study visits at Dartmouth College while receiving cancer care at Dartmouth-Hitchcock Medical Center.

Condition or Disease Intervention/Treatment Phase
  • Other: Specialty Palliative Care
N/A

Detailed Description

A feasibility pilot open label, single-arm observational case series of 10 patients with metastatic gastrointestinal and lung cancer patients and 10 care partners. Participants will complete two study visits, separated by approximately 8-16 weeks of usual oncologic care with early integrated specialty palliative care. The palliative care physician will also be a study participant.

Primary Objective: To develop and refine study procedures which can be used in future research in order to further understanding of the mechanisms of action of specialty palliative. Expected products: manual of operating procedures and web-based data collection forms.

Secondary Objectives: To test the feasibility of conducting a mechanism-focused clinical trial of primary palliative care vs. specialty palliative care for advanced cancer patients and their care partners. Expected products: preliminary data demonstrating the feasibility of study procedures sufficient to prove this study design is possible.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
20 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Health Services Research
Official Title:
The Science of the Art of Palliative Care Pilot
Anticipated Study Start Date :
Sep 1, 2022
Anticipated Primary Completion Date :
Jun 30, 2023
Anticipated Study Completion Date :
Jun 30, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Arm 1

Patients and care partners receive specialty primary care and participate in pre- and post- functional MRI scans to measure the effects of the specialty palliative care intervention.

Other: Specialty Palliative Care
Specialty palliative care, as opposed to primary palliative care.

Outcome Measures

Primary Outcome Measures

  1. Operationalization as measured by the creation of a manual of operating procedures and web-based data collection forms [6 months]

    Establish acceptable operating procedures and data collection instruments which can be replicated for future projects.

Secondary Outcome Measures

  1. Feasibility as measured by participant interest [6 months]

    Percent of participants approached and interested in participating

  2. Feasibility as measured by enrollment number [6 months]

    Percent of participants approached and enrolled

  3. Feasibility as measured by willingness to be randomized [6 months]

    Percent of participants enrolled and willing to be randomized

  4. Feasibility as measured by procedure completion rate [6 months]

    Percent of participants randomized and completed procedures (specialty palliative care, fMRIs, surveys, bio response measurements).

  5. Feasibility as measured by participant withdrawal rate [6 months]

    Percent of participants not completing each study visit and specialty primary care visit

  6. Tolerability as measured by subjective units of distress scores (SUDS, 0-100) [6 months]

    The SUDs Rating Scale, or Subjective Units of Distress Scale (SUDs) as it is officially known, is used to measure the intensity of distress or nervousness in people with social anxiety. The SUDs is a self-assessment tool rated on a scale from 0 to 100.

  7. Tolerability as measured by rates of study procedure non-completion. [6 months]

    Percent of participants not completing each study procedures (specialty palliative care, fMRIs, surveys, bio response measurements).

  8. Acceptability as measured by response to questions of level of burden. [6 months]

    Two closed-ended Likert scale items regarding study burdensomeness. (this investigator-created instrument is in development)

  9. Acceptability as measured by willingness to recommend study participation to others. [6 months]

    Measured by the Net Promoter Score - The Net Promoter Score is an index that measures the willingness of participants to recommend a services to others. It is used as a proxy for gauging overall satisfaction with a service. Net Promoter Score (scale from 0 to 10 with 3 groups: promoters for 9-10, passive for 7-8 and detractor for below 6).

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • 18 years or older

  • Patient: has received a diagnosis of metastatic lung or gastrointestinal cancer within the last 8 weeks *(note: most metastatic GI cancer will likely be pancreatic or colorectal)

  • Care partner: care partner of a patient who has received a diagnosis of metastatic lung or gastrointestinal cancer who has provided consent for study (either with our without functional MRI study visits)

  • Be able to understand study requirements and make an informed decision to participate

  • Be able to speak and read English

Exclusion Criteria:
  • Life expectancy of <8 weeks

  • Known brain metastases

  • Claustrophobia

  • Contraindications to MRI (e.g.: implanted or embedded metal/metal fragments. Metals in the body make the participant unable to undergo an MRI which makes them ineligible for study participation).

Contacts and Locations

Locations

Site City State Country Postal Code
1 Dartmouth-Hitchcock Medical Center Lebanon New Hampshire United States 03756

Sponsors and Collaborators

  • Dartmouth-Hitchcock Medical Center
  • Dartmouth College

Investigators

  • Principal Investigator: Amber Barnato, MD, Dartmouth-Hitchcock Medical Center

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Amber Barnato, Director, The Dartmouth Institute, Dartmouth-Hitchcock Medical Center
ClinicalTrials.gov Identifier:
NCT05137782
Other Study ID Numbers:
  • STUDY02001223
First Posted:
Nov 30, 2021
Last Update Posted:
Jul 27, 2022
Last Verified:
Jul 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Amber Barnato, Director, The Dartmouth Institute, Dartmouth-Hitchcock Medical Center
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 27, 2022